(Date:1/8/2009)...TY, Jan. 8 In response to a critic...nationwide, ARUP Laboratories, a national medical ...boratory research and development, and Weber Stat...rning arena, have partnered to promote and facilit...d medical laboratory technicians (MLT). ARUP and W...
(Date:1/8/2009)...f Government Officials Expect to Maintain or Incre...onstruction of Roads and Bridges, Creation of 21st...icient Government Facilities , , SEATTLE, Jan. ... Obama,s economic stimulus package outlines a sign...ady" construction of roads and bridges, 21st-centu...
(Date:1/8/2009)...ncy reception sets stage for productive partnershi...icare Advocacy Recovery Coalition (MARC), a broad-...or reform, laid the groundwork for improving the M...gural meeting with officials from the Center for M...urpose was to introduce MARC as an industry resour...
(Date:1/8/2009)...n linguistic and cultural differences of native pe...ws) -- Genetic evidence suggests that two differen...a at about the same time to become the first settl...oximately 15,000 to 17,000 years ago, one group of...dmass, which once connected northeast Siberia to A...
Breaking Medicine News(10 mins):Health News:ARUP Laboratories and Weber State University Team Up to Provide Laboratory Education Solutions 2Health News:ARUP Laboratories and Weber State University Team Up to Provide Laboratory Education Solutions 3Health News:ARUP Laboratories and Weber State University Team Up to Provide Laboratory Education Solutions 4Health News:Government at all Levels Will Continue to Spend on Essential Services and Invest in the Future, According to Onvia Study 2Health News:Government at all Levels Will Continue to Spend on Essential Services and Invest in the Future, According to Onvia Study 3Health News:Government at all Levels Will Continue to Spend on Essential Services and Invest in the Future, According to Onvia Study 4Health News:MARC Coalition Holds Initial Meeting With CMS; Announces New Members 2Health News:First Americans Arrived on 2 Separate Paths 2...harmless, but it looks awful. Worse, it's a real p...ngue (lingua villosa nigra) occurs when the papill...row up to 1.5 cm in length and turn black or brown... the University of Essen. It occurs most regularly...
...een geographic convenience and the quality of serv...remote areas, according to an article// in the lat...JA). There is a developing trend towards urban ce...rvices, driven by a need to maintain service quali...
...c survey conducted by Dr. David Schutt of Thomson ...m it was found that more than three-quarters// of ...are healthy. About 11,000 people were contacted b...hey did vigorous exercise for times a week. About ...
...e 2 diabetes could also be at risk of chronic kidn...test issue of the Medical Journal of Australia.// ... of Renal Impairment cO-existing with NIDDM (non-i...is one of the largest studies of type 2 diabetes e...
Other Medicine News:Health News:Bolster Rural Surgical Services 2(Date:1/6/2009)...swire-USNewswire/ -- Sequella, Inc., a clinical-st...of epidemic potential, announced today that SQ109,...rculosis (TB), was the first drug approved for eva...ct to Dynport Vaccine Company LLC and Quintiles Tr... Institute of Allergy and Infectious Diseases (NIA...
(Date:1/5/2009).../ -- Cylene Pharmaceuticals announced today that i...al CK2 protein kinase inhibitor, CX-4945, in patie...e, or multiple myeloma. The primary endpoints of t... safety, tolerance and PK properties of CX-4945 an...ls. In addition, multiple mechanism-related pharma...
(Date:12/30/2008)...re-USNewswire/ -- The Coalition for 21st Century M...d by Genentech, Inc. on December 5, 2008, seeking ...iagnostic tests to physicians and patients. The r...ould harm patient care and rests on flawed scienti...sion is to encourage the research, development, an...
(Date:12/27/2008)...year silence, offers to ease cloning costs for Clo..., Dec. 27 Six years to ...ned child, Dr. Brigitte Boisselier, head of the co... other babies cloned by her company are growing up...ir families, privacy. , , "We,ve helped almost ...
Breaking Medicine Technology:Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4'We're Ready to Prove It!' 2Dairy Veterinarians Highlight Need for Improved Methods for Detecting Mastitis 28046 1Dairy Veterinarians Highlight Need for Improved Methods for Detecting Mastitis 28046 2Cardinal Health Reports First Quarter Results 28043 1Cardinal Health Reports First Quarter Results 28043 2Cardinal Health Reports First Quarter Results 28043 3Cardinal Health Reports First Quarter Results 28043 4Cardinal Health Reports First Quarter Results 28043 5Cardinal Health Reports First Quarter Results 28043 6Cardinal Health Reports First Quarter Results 28043 7Cardinal Health Reports First Quarter Results 28043 8Cardinal Health Reports First Quarter Results 28043 9Cardinal Health Reports First Quarter Results 28043 10Cardinal Health Reports First Quarter Results 28043 11Cardinal Health Reports First Quarter Results 28043 12Cardinal Health Reports First Quarter Results 28043 13Cardinal Health Reports First Quarter Results 28043 14Cardinal Health Reports First Quarter Results 28043 15Cardinal Health Reports First Quarter Results 28043 16Cardinal Health Reports First Quarter Results 28043 17Cardinal Health Reports First Quarter Results 28043 18Cardinal Health Reports First Quarter Results 28043 19Cardinal Health Reports First Quarter Results 28043 20Cardinal Health Reports First Quarter Results 28043 21Cardinal Health Reports First Quarter Results 28043 22Cardinal Health Reports First Quarter Results 28043 23DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective 8682 1DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective 8682 2DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective 8682 3DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective 8682 4CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011 vcMMAE Phase II Trial Results on November 3 200 3360 1CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011 vcMMAE Phase II Trial Results on November 3 200 3360 2...-Jun 25, 2007 - CytRx Corporation,(NASDAQ:CYTR), a...ent and commercialization of human therapeutics, t... its previously,announced double-blind, placebo-co...ealthy volunteers with its drug candidate,arimoclo... support,the use of arimoclomol in future clinical...
...WIRE)--Jun 25, 2007 - Affymax, Inc.,(Nasdaq:AFFY) ...rial results for Hematide(TM) were presented at th...eld in Barcelona, Spain by Iain C.,Macdougall, M.D...don. Dr. Macdougall,s poster included data in prev...ve, non-dialysis patients which,demonstrated that ...
Other Medicine Technology:CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 2CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 3CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 4CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 5Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 2Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 3...ity Biotech Captia Mumps IgG Enzyme-linked Im...ction and quantitative determination of IgG antibo...specimens may be used for the determination of imm...ay be used to demonstrate seroconversion or a sign...
The DSL-05-10-MUG Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Mumps Virus in human serum. This assay is intended for in
...nal treatment of diseases of the thoracic aorta ha...ision in the chest to place a synthetic graft to r...in long hospital stays and painful recoveries. Tod... alternatives to this major open surgical approach...
...lagship product, the Super Premium ALPHA 10 System... versatility in an intuitive and ergonomically des...tem for Perinatology/Maternal & Fetal Medicine Spe...ons, Breast Imaging, and General Imaging departmen...
Medicine Products: